Insider Selling: Paysign (NASDAQ:PAYS) EVP Sells 38,900 Shares of Stock

Paysign, Inc. (NASDAQ:PAYS) EVP Joan Herman sold 38,900 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $11.74, for a total value of $456,686.00. Following the completion of the sale, the executive vice president owned 609,421 shares of the company’s stock, valued at approximately $7,154,602.54. The trade was a 6.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paysign Stock Performance

Shares of NASDAQ PAYS traded up $0.60 during trading on Thursday, hitting $12.42. 899,844 shares of the company were exchanged, compared to its average volume of 745,622. Paysign, Inc. has a 12-month low of $3.08 and a 12-month high of $14.43. The company has a fifty day moving average price of $11.46 and a 200-day moving average price of $8.01. The firm has a market capitalization of $701.23 million, a PE ratio of 47.77 and a beta of 0.80.

Paysign (NASDAQ:PAYS) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.05. Paysign had a net margin of 15.67% and a return on equity of 30.13%. The firm had revenue of $28.25 million during the quarter, compared to analysts’ expectations of $26.36 million. Paysign has set its FY 2026 guidance at 0.350-0.370 EPS and its Q3 2026 guidance at 0.090-0.100 EPS. Research analysts anticipate that Paysign, Inc. will post 0.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PAYS has been the subject of several analyst reports. Wall Street Zen lowered Paysign from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. Barrington Research set a $15.00 price target on Paysign in a report on Tuesday, August 11th. Lake Street Capital raised their price objective on Paysign from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday. DA Davidson raised their price objective on Paysign from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings raised shares of Paysign from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, July 29th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $14.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Tidal Investments LLC purchased a new position in shares of Paysign during the second quarter worth $121,000. Connective Capital Management LLC acquired a new position in Paysign during the 2nd quarter worth about $327,000. Corient Private Wealth LP boosted its holdings in Paysign by 69.8% during the 2nd quarter. Corient Private Wealth LP now owns 30,159 shares of the company’s stock valued at $247,000 after acquiring an additional 12,396 shares during the period. Punch & Associates Investment Management Inc. purchased a new position in Paysign during the 2nd quarter valued at about $16,983,000. Finally, Bank of America Corp DE acquired a new position in Paysign in the 2nd quarter valued at about $335,000. 25.89% of the stock is currently owned by institutional investors and hedge funds.

About Paysign

Paysign, Inc is a financial technology company that provides payment and financial services primarily to the healthcare and pharmaceutical industries. Its platform supports prepaid card programs, digital payments and other disbursement solutions designed to help organizations distribute funds to individuals efficiently and securely.

The company’s services include patient assistance programs that help eligible patients receive financial support for prescription medications and other healthcare costs.